Form: 8-K

Current report filing

March 25, 2004

8-K: Current report filing

Published on March 25, 2004


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934


Date of report (Date of earliest event reported): March 25, 2004




Access Pharmaceuticals, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)


Delaware 0-9314 83-0221517
- ------------------------ ------------------------ -------------------
(State of Incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)


2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207
----------------------------------------------- ---------
(Address of principal executive offices) (Zip Code)


Registrant's telephone number, including area code: (214) 905-5100
--------------



Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
------------------------------------------------------------------
(c) Exhibits
--------
99.1 Access Pharmaceuticals, Inc. Press Release, dated March 25, 2004.


Item 12. Disclosure of Results of Operations and Financial Condition.
------------------------------------------------------------
Access Pharmaceuticals, Inc. issued a press release on March 25, 2005, a
copy of which is attached as Exhibit 99.1 to this report and incorporated
herein by this reference, in which it announced that on March 25, 2004
it will report its financial results for the fourth quarter and the
year ended December 31, 2003. It will have a conference call on
March 25, 2004 to discuss the results. This information shall not be
deemed to be "filed" for the purposes of Section 18 of the
Securities Exchange Act of 1934 and shall not be deemed to be
incorporated by reference in any filing under the Securities Act of 1933.






2

SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.



Access Pharmaceuticals, Inc.
(Registrant)

By: /s/ Stephen B. Thompson
------------------
Stephen B. Thompson
Vice President and
Chief Financial Officer

Dated March 25, 2004

3

EXHIBIT INDEX

Exhibit
Number Description
- ------- ------------
99.1 Press Release, date March 25, 2004

4